Toxic Thyroid Nodule

Chapter: Toxic Thyroid Nodule
McMaster Section Editor(s): Victor M. Montori, Juan P. Brito
Section Editor(s) in Interna Szczeklika: Barbara Jarząb, Ewa Płaczkiewicz-Jankowska
McMaster Author(s): Juan P. Brito
Author(s) in Interna Szczeklika: Barbara Jarząb, Ewa Płaczkiewicz-Jankowska
Additional Information

Definition, Etiology, Pathogenesis Top

A toxic thyroid nodule is an adenoma (toxic adenoma) or hyperplastic nodule observed on radionuclide scintigraphy that usually (but not always) causes hyperthyroidism. It develops most commonly as a result of a somatic mutation of the thyrotropin-stimulating hormone receptor or stimulatory G protein alpha subunit (Gs alpha). Unlike multinodular goiter, it is not related to iodine deficiency.

Clinical Features Top

Symptoms of hyperthyroidism are similar to those caused by toxic multinodular goiter, and the typical pattern of development is from a compensated autonomously functioning nodule to overt hyperthyroidism: see Figure 5.6-9.

Diagnosis Top

Diagnosis is based on radionuclide thyroid scintigraphy. Clinical examination and ultrasonography reveal a solitary nodule. TSH secretion can be decreased (but still within normal limits) or suppressed (subclinical or overt hyperthyroidism [see Thyrotoxicosis]).

Treatment Top

The treatment of choice is radioiodine therapy (see Table 5.6-6). Due to low serum TSH levels, iodine uptake of the thyroid parenchyma is inhibited (therefore, the risk of developing posttreatment hypothyroidism is low). Radioiodine therapy should be started after discontinuation of thionamides and when serum TSH levels are <0.1 mIU/L. In patients with indications for fine-needle biopsy (see Nontoxic Multinodular Goiter), the biopsy should not be performed within 1 to 2 weeks before radioiodine therapy, as it may cause transient inhibition of iodine uptake by the nodule. Serum TSH levels should be monitored and follow-up ultrasonography performed to evaluate the size of the nodule every 6 to 12 months. In some centers ethanol injections into the nodule are used with satisfactory outcomes.

Prognosis Top

The 6-year risk of developing overt hyperthyroidism in patients with a compensated or subtoxic nodule (ie, with subclinical thyrotoxicosis) is 2% to 5%. With appropriately conducted radioiodine therapy a complete resolution of hyperthyroidism may be achieved. The risk of malignancy is ~2%.

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.